2. Powerful support from abundant platforms
After 7 years of continuous innovation, the series platforms of Sanyou Bio including antibody generation, antibody engineering, in-vitro and in-vivo efficacy evaluation, production cell line construction, and pilot fermentation have formed its unique technical barriers and core competitiveness, which greatly support integrated R&D platform for innovative antibody drugs.
2.1. Featured Platform I:Super-trillion library size of innovative antibody drug discovery platform
✔ Ten-trillion-level library capacity
✔ Thousands of lead molecules for initial screening
✔ Full coverage of molecule forms
✔ Multiple pathways for molecule generation
✔ Fit to challenging targets
✔ In-depth validation through nearly one hundred projects
✔ Matching with one-stop and high-throughput screening service
Trillion fully human antibody library
✔ Trillion library capacity
✔ Recombinant antibody library based on human B cell antibody gene
✔ Derived from nature with high druggability
✔ Median lead molecules: Over 300
Trillion fully human semi-synthetic antibody library
✔ Trillion library capacity
✔ Antibody library based on human B cell antibody gene rearrangement
✔ Derived from nature along with engineering design and high diversity
✔ Median lead molecules: Over 300
Trillion humanized 2C-type single domain antibody library
✔ 2-trillion library capacity
✔ The humanization degree based on framework is as high as 98%
✔ 2C-type single domain synthetic antibody library
✔ Median lead molecules: Over 600
✔ 2-trillion library capacity
✔ The humanization degree based on framework is as high as 98%
✔ 4C-type single domain synthetic antibody library that is theoretically more stable and more degradation-resistant
✔ Median lead molecules: Over 600
✔ Trillion library capacity
✔ Recombinant antibody library with a combination of selected light chains and diversified heavy chains
✔ Derived from fully human naive antibodies, with selected light chains and diversified heavy chains
✔ Median lead molecules: Over 300
Trillion cyclic polypeptide library
✔ Trillion library capacity
✔ A cyclic polypeptide library with fusion of selected tagged proteins and natural cyclic polypeptides
✔ Fit for the R&D of PDC, oral, and intracellular targets
✔ Median lead molecules (estimated): Over 100
✔ Large library capacity and definite sequences costing months less compared with hybridoma method
✔ Diversified antigens, mouse, immunization method, and screening method
✔ Recombinant antibody library base on mouse B cell antibody genes after immunization
✔ Median lead molecules: Over 40
✔ Large library capacity and definite sequences
✔ Diversified antigens, mouse, immunization method, and screening method
✔ Single domain antibody obtained directly
✔ Median lead molecules: Over 30
2.2. Featured Platform II: Antibody engineering platform
✔ 3D deep humanization design
✔ Distinctive database with reliable design
✔ Rich project experience and high success rate
✔ Eukaryotic expression system with natural modification
✔ Fast and qualified delivery within 4 to 6 weeks
✔ Ultimate improvement of affinity activity
✔ Comprehensive verification of eukaryotic expression
✔ No limit on target types
✔ Rich project R&D experience
✔ Fast and qualified delivery within 6 weeks
2.3. Featured Platform III: Platform for efficacy evaluation in animal models
✔ Variety of mouse strains and disease models
✔ Standardized animal room and management system
✔ High-quality and customized one-stop service
✔ Rich project R&D experience
✔ Fast and qualified delivery within 56 days
2.4. Featured Platform IV: Platform for production cell line development
✔ High yield: Expression level of bispecific monoclonal antibody cell line in flask is up to 9.0 g/L
✔ Stable production: Over 60 PDL assessments are performed to support commercialized production.
✔ Premium quality: 11 assessment indicators are used to ensure expression production quality.
✔ Good compliance: cGMP standards are adopted and 4 sets of commercially authorized host cells are available.
✔ Ultra fast: It takes only 2.5 months to obtain monoclonal cell lines.
2.5. Featured Platform V: Platform for antibody fermentation process development
✔ Antibody yield up to 12 g/L
✔ Compliance with antibody quality standards
✔ Four sets of authorized host cells